TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TADALAFIL

TADALAFIL Phosphodiesterase 5 Inhibitors
Approved 2018-05-22
18
Indications
--
Phase 3 Trials
7
Years on Market

TADALAFIL Approval History

Loading approval history...

What TADALAFIL Treats

2 indications

TADALAFIL is approved for 2 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Erectile Dysfunction
  • Benign Prostatic Hyperplasia
Source: FDA Label

Drugs Similar to TADALAFIL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CIALIS
TADALAFIL
2 shared
Eli Lilly
Shared indications:
Erectile DysfunctionBenign Prostatic Hyperplasia
AVANAFIL
AVANAFIL
1 shared
HETERO LABS LTD V
Shared indications:
Erectile Dysfunction
AVODART
DUTASTERIDE
1 shared
WAYLIS THERAP
Shared indications:
Benign Prostatic Hyperplasia
CARDURA
DOXAZOSIN MESYLATE
1 shared
Viatris
Shared indications:
Benign Prostatic Hyperplasia
CARDURA XL
DOXAZOSIN MESYLATE
1 shared
Viatris
Shared indications:
Benign Prostatic Hyperplasia
CAVERJECT IMPULSE
ALPROSTADIL
1 shared
Pfizer
Shared indications:
Erectile Dysfunction
DOXAZOSIN MESYLATE
DOXAZOSIN MESYLATE
1 shared
ZYDUS PHARMS
Shared indications:
Benign Prostatic Hyperplasia
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
DUTASTERIDE
1 shared
Aurobindo Pharma
Shared indications:
Benign Prostatic Hyperplasia
EDEX
ALPROSTADIL
1 shared
ENDO OPERATIONS
Shared indications:
Erectile Dysfunction
GEMTESA
VIBEGRON
1 shared
SUMITOMO PHARMA AM
Shared indications:
Benign Prostatic Hyperplasia
JALYN
DUTASTERIDE
1 shared
WAYLIS THERAP
Shared indications:
Benign Prostatic Hyperplasia
PROSCAR
FINASTERIDE
1 shared
Merck
Shared indications:
Benign Prostatic Hyperplasia
SILODOSIN
SILODOSIN
1 shared
PRINSTON INC
Shared indications:
Benign Prostatic Hyperplasia
STENDRA
AVANAFIL
1 shared
VIVUS LLC
Shared indications:
Erectile Dysfunction
UROXATRAL
ALFUZOSIN HYDROCHLORIDE
1 shared
ADVANZ PHARMA
Shared indications:
Benign Prostatic Hyperplasia
VARDENAFIL HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE
1 shared
ZYDUS PHARMS
Shared indications:
Erectile Dysfunction
VIAGRA
SILDENAFIL CITRATE
1 shared
Viatris
Shared indications:
Erectile Dysfunction
VYBRIQUE
SILDENAFIL CITRATE
1 shared
IBSA
Shared indications:
Erectile Dysfunction
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TADALAFIL FDA Label Details

Pro

Indications & Usage

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) the signs and symptoms of benign prostatic hyperplasia (BPH) ED and the signs and symptoms of BPH (ED/BPH) If tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks . 1.1 Erectile Dysfunction Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED). 1.2 Benign Prostatic Hyperplasia Tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). 1.3 Erectile Dysfunc...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.